Protocol Number: EYE-RES-103
Principal Investigator: Scott Westhouse, DO
A Randomized, Double-Masked, Mulit-Center, 3-Arm Phase 2/3 to Evaluate the Efficacy and Safety of Intravitreal EYE103 Compared with Intravitreal Ranibizumab (0.5mg) in Participants with DME.